Follow
Ghada F. Ahmed, PhD
Title
Cited by
Cited by
Year
Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy
YG Puranik, AK Birnbaum, SE Marino, G Ahmed, JC Cloyd, RP Remmel, ...
Pharmacogenomics 14 (1), 35-45, 2013
1272013
OA 09.03 TATTON Ph Ib expansion cohort: osimertinib plus savolitinib for pts with EGFR-mutant MET-amplified NSCLC after progression on prior EGFR-TKI
M Ahn, J Han, L Sequist, BC Cho, JS Lee, S Kim, W Su, C Tsai, JC Yang, ...
Journal of Thoracic Oncology 12 (11), S1768, 2017
492017
A phase Ib study of the highly selective MET-TKI savolitinib plus gefitinib in patients with EGFR-mutated, MET-amplified advanced non-small-cell lung cancer
JJ Yang, J Fang, YQ Shu, JH Chang, GY Chen, JX He, W Li, XQ Liu, ...
Investigational New Drugs 39, 477-487, 2021
452021
SAVANNAH: A Phase II trial of osimertinib plus savolitinib for patients (pts) with EGFR-mutant, MET-driven (MET+), locally advanced or metastatic non-small cell …
GR Oxnard, M Cantarini, P Frewer, G Hawkins, J Peters, P Howarth, ...
Journal of Clinical Oncology 37 (15_suppl), TPS9119-TPS9119, 2019
412019
Inhibition of Pseudomonas aeruginosa PAO1 adhesion to and invasion of A549 lung epithelial cells by natural extracts
GF Ahmed, WF Elkhatib, AM Noreddin
Journal of infection and public health 7 (5), 436-444, 2014
342014
A pharmacotherapy capstone course to advance pharmacy students’ clinical documentation skills
JM Conway, GF Ahmed
American journal of pharmaceutical education 76 (7), 134, 2012
342012
OA 09.06 A phase Ib trial of savolitinib plus gefitinib for chinese patients with EGFR-mutant MET-amplified advanced NSCLC
J Fang, Y Shu, J Chang, G Chen, J He, W Li, X Liu, N Yang, C Zhou, ...
Journal of Thoracic Oncology 12 (11), S1769, 2017
232017
Population pharmacokinetics of unbound and total drug concentrations following intravenously administered carbamazepine in elderly and younger adult patients with epilepsy
GF Ahmed, RC Brundage, SE Marino, JC Cloyd, IE Leppik, PB Pennell, ...
The Journal of Clinical Pharmacology 53 (3), 276-284, 2013
222013
Pharmacokinetics and saturable absorption of gabapentin in nursing home elderly patients
GF Ahmed, SPR Bathena, RC Brundage, IE Leppik, JM Conway, ...
The AAPS journal 19, 551-556, 2017
202017
Pharmacokinetic–pharmacodynamic modelling of intravenous and oral topiramate and its effect on phonemic fluency in adult healthy volunteers
GF Ahmed, SE Marino, RC Brundage, SVS Pakhomov, IE Leppik, ...
British Journal of Clinical Pharmacology 79 (5), 820-830, 2015
182015
Pharmacodynamics of moxifloxacin versus vancomycin against biofilms of methicillin-resistant Staphylococcus aureus and epidermidis in an in vitro model
AH Salem, WF Elkhatib, GF Ahmed, AM Noreddin
Journal of Chemotherapy 22 (4), 238-242, 2010
92010
Savolitinib±osimertinib in Japanese patients with advanced solid malignancies or EGFRm NSCLC: Ph1b TATTON Part C
K Yoh, T Hirashima, H Saka, T Kurata, Y Ohe, T Hida, A Mellemgaard, ...
Targeted Oncology 16 (3), 339-355, 2021
82021
A pharmacokinetic–pharmacodynamic model for the MET tyrosine kinase inhibitor, savolitinib, to explore target inhibition requirements for anti‐tumour activity
RDO Jones, M Grondine, A Borodovsky, M San Martin, M DuPont, ...
British Journal of Pharmacology 178 (3), 600-613, 2021
82021
A randomized, double‐blind, placebo‐and positive‐controlled, three‐way crossover study in healthy participants to investigate the effect of savolitinib on the QTc interval
T Sahota, CD Dota, T Vik, W Yan, RB Verheijen, S Walker, Y Li, ...
Clinical Pharmacology in Drug Development 10 (5), 521-534, 2021
72021
FRI0156 pharmacokinetics of ABT-122, a dual TNF-and IL-17A-targeted DVD-IG™, after single dosing in healthy volunteers and multiple dosing in subjects with rheumatoid arthritis
GF Ahmed, S Goss, P Jiang, H Mansikka, RJ Padley, AA Othman
Annals of the rheumatic diseases 74 (Suppl 2), 479-479, 2015
72015
P1. 01-134 SAVANNAH: phase II trial of osimertinib+ savolitinib in EGFR-mutant, MET-driven advanced NSCLC, following prior osimertinib
M Ahn, M Cantarini, P Frewer, G Hawkins, J Peters, P Howarth, G Ahmed, ...
Journal of Thoracic Oncology 14 (10), S415-S416, 2019
62019
Application of Pharmacokinetics/Pharmacodynamics (PK/PD) in Designing Effective Antibiotic Treatment Regimens
GF Ahmed, AM Noreddin
Readings in Advanced Pharmacokinetics: Theory, Methods and Applications, 388, 2012
42012
Parent and metabolite concentration-QT modeling to evaluate QT-interval prolongation at savolitinib therapeutic doses
S Schalkwijk, T Sahota, RB Verheijen, AR Harmer, GF Ahmed
The AAPS Journal 23, 1-10, 2021
32021
The Effect Of Methotrexate On Adalimumab Pharmacokinetics: Pooled Analysis Of Adalimumab Pharmacokinetics In Patients With Rheumatoid Arthritis After Subcutaneous Administration.
W Awni, S Pilari, G Ahmed, P Noertersheuser
Arthritis and Rheumatism 65, S214-S214, 2013
32013
Adalimumab in combination with high and low dose-methotrexate in rheumatoid arthritis patients with inadequate response to methotrexate: pharmacokinetic results from the MUSICA …
G Ahmed, SL Goss, CE Klein, N Mozaffarian, GS Kaeley, W Awni
ARTHRITIS AND RHEUMATISM 65, S623-S624, 2013
32013
The system can't perform the operation now. Try again later.
Articles 1–20